頁籤選單縮合
| 題 名 | 新作用機轉的降血糖藥--Canagliflozin=A New Class of Antidiabetic Agent--Canagliflozin |
|---|---|
| 作 者 | 劉素靜; 黃佳真; 項怡平; | 書刊名 | 藥學雜誌 |
| 卷 期 | 31:4=125 2015.12[民104.12] |
| 頁 次 | 頁27-30 |
| 分類號 | 418.271 |
| 關鍵詞 | 糖尿病; SGLT2抑制劑; Canagliflozin; HbA1c; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | Canagliflozin 為一 SGLT2抑制劑的降血糖藥物,適用於其它作用機轉以外口服降 血糖藥物控制不佳的第二型糖尿病人,canagliflozin 可降低 HbA1c 與空腹血糖值,卻 不會增加患者的體重,因此它在治療上的好處是除降血糖之外,又不會引起低血糖, 但是需特別注意的是老年人或腎功能不好者使用需小心,因此基於上述理由,對於第 二型糖尿病人而言 canagliflozin 是一耐受性佳的藥物。 |
| 英文摘要 | Canagliflozin is a SGLT2 inhibitor developed for the treatment of type 2 diabetes,suitable for patients with type 2 diabetes inadequately controlled with other oral antihyperglycermic medicine. Canagliflozin has been associated with reductions in glycated haemoglobin A1c (HbA1c), fasting plasma,but not increase body weight .Thus,it can provide glycaemic control while having beneficial effect on hypoglycaemia,but should be carefully apply for elderly patient or those with renal impairment. Thus, canagliflozin may recognized as well tolerated, for type 2 diabetes. |
本系統中英文摘要資訊取自各篇刊載內容。